Once-Weekly Epoetin Alfa Dosing Is as Effective as Three Times-Weekly Dosing in Increasing Hemoglobin Levels and Is Associated with Improved Quality of Life in Anemic HIV-Infected Patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 4, 2003, Pages 368-378

  Grossman, Howard A ^a,c   Goon, Betty ^b   Bowers, Peter ^b   Leitz, Gerhard ^b  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

^b Ortho Biotech Products LP   (United States)

^c Polari Medical Group   (United States)

Author keywords

Anemia; Epoetin alfa; Hemoglobin; HIV; Quality of life

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; PARAMETER; PATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANEMIA; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 0345256378     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200312010-00003     Document Type: Article

References (40)

1. Hambleton J. Hematologic complications of HIV infection. Oncology. 1996;10:671-680.
2. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. The Adult/Adolescent Spectrum of Disease Group. Blood. 1998;91:301-308.
3. Bain BJ. Pathogenesis and pathophysiology of anemia in HIV infection. Curr Opin Hematol. 1999;6:89-93.
4. Creagh T, Mildvan D, Bohn H, et al. A case-control study to examine the association of anemia with HIV/AIDS progression: results from the 1996 enrollment cohort [poster 1049]. Presented at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001.
5. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990;322:1488-1493.
6. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med. 1992;117:739-748.
7. Henry DH. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia. Semin Oncol. 1998;25(Suppl 7):64-68.
8. Revicki DA, Brown RE, Henry DH, et al. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:474-484.
9. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS. 2000;11:659-665.
10. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients across Europe. EuroSIDA Study Group. AIDS. 1999;13:943-950.
11. Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDs. 2001;15:473-480.
12. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
13. Volberding P. Consensus statement: anemia in HIV infection-current trends, treatment options, and practice strategies. The Anemia in HIV Working Group. Clin Ther. 2000;22:1004-1020.
14. Sharp V, Paredes J, Steinbock C. Anemia in HIV disease in the HAART era: is it common? [abstract 3179]. Blood. 1999;94(Suppl 1, Part 2):8b.
15. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Inter-agency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28-35.
16. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:29-33.
17. Moore R. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis. 1999;29:44-49.
18. Lewden C, Leport C, Cuzin L, et al. Prognostic factors of mortality in the APROCO-ANRS EP cohort of HIV-1 infected adults started on a protease inhibitor-containing therapy [abstract 1909]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000.
19. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002;185:178-187.
20. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol. 2001;57:411-418.
21. Provenzano R, Fink J, Suchinda P. POWER Study Group. Once-weekly (QW) PROCRIT is effective in treating the anemia of chronic kidney disease (CKD): final results from the POWER study [abstract SU-P0837]. J Am Soc Nephrol. 2002;13:641A.
22. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
23. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy [abstract 1866]. Blood. 2000;96(Part 1):434a.
24. Wasserman R, Brau N, Hassanein TI, et al. Once weekly epoetin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/INF therapy [abstract 833]. Hepatology. 2000;32:368A. Poster presented at the 51 st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, 2000.
25. Wasserman R, Brau N, Hassanein TI, et al. Once weekly epoetin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/INF therapy [abstract 833]. Hepatology. 2000;32:368A. Poster presented at the 51 st Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, 2000.
26. Sulkowski M, Wasserman R, Brooks LJ, et al. Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic HCV infection [poster]. Presented at Digestive Diseases Week, Atlanta, 2001.
27. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
28. Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
29. Delate T, Coons SJ. The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis. 2001;32(Suppl):E47-E52.
30. Badia X, Podzamczer D, Casado A, et al, and the Spanish MOS-HIV and MQOL-HIV Validation Group. Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. AIDS. 2000;14:1439-1447.
31. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care. 1998;36:126-137.
32. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
33. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
34. Saag MS, Levine AM, Leitz GJ, et al. Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV-positive patients [abstract 708]. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, 2001.
35. Dawson J, Fitzpatrick R, Frost S, et al. Evidence for the validity of a patient-based instrument for assessment of outcome after revision hip replacement. J Bone Joint Surg Br. 2001;83:1125-1129.
36. Wu AW, Rubin HR, Mathews WC, et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1993;6:452-458.
37. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life versus placebo. A randomized, double-blind, multicenter study [abstract 505]. Gastroenterology. 2003;124(Suppl 1):A-714.
38. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
39. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:315-319.
40. Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Semin Hematol. 2000;37(Suppl 6):18-23.